Abstract Previous studies suggest that melatonin may act on cancer growth through a variety of mechanisms, most notably by direct anti-proliferative effects on breast cancer cells and via interactions with the estrogen pathway. Three genes are largely responsible for mediating the downstream effects of melatonin: melatonin receptors 1a and 1b (MTNR1a and MTNR1b), and arylalkylamine N-acetyltransferase (AANAT). It is hypothesized that genetic variation in these genes may lead to altered protein production or function. To address this question, we conducted a comprehensive evaluation of the association between common single nucleotide polymorphisms (SNPs) in the MTNR1a, MTNR1b, and AANAT genes and breast cancer risk among 2,073 cases and 2,083 controls, using a twostage analysis of genome-wide association data among women of the Shanghai Breast Cancer Study. Results demonstrate two SNPs were consistently associated with breast cancer risk across both study stages. Compared with MTNR1b rs10765576 major allele carriers (GG or GA), a decreased risk of breast cancer was associated with the AA genotype (OR = 0.78, 95% CI = 0.62-0.97, P = 0.0281). Although no overall association was seen in the combined analysis, the effect of MTNR1a rs7665392 was found to vary by menopausal status (P-value for interaction = 0.001). Premenopausal women with the GG genotype were at increased risk for breast cancer compared with major allele carriers (TT or TG) (OR = 1.57, 95% CI = 1.07-2.31, P = 0.020), while postmenopausal women were at decreased risk (OR = 0.58, 95% 0.36-0.95, P = 0.030). No significant breast cancer associations were found for variants in the AANAT gene. These results suggest that common genetic variation in the MTNR1a and 1b genes may contribute to breast cancer susceptibility, and that associations may vary by menopausal status. Given that multiple variants in high linkage disequilibrium with MTNR1b rs76653292 have been associated with altered function or expression of insulin and glucose family members, further research may focus on clarifying this relationship.
Introduction
Melatonin is a hormone produced by the pineal gland and is released in response to photic information from the retina. In humans, melatonin secretion increases soon after exposure to darkness, peaks during the middle of the night, and then decreases over the second half of the night [1] . The role for melatonin in breast cancer etiology was hypothesized as early as the late 1970s and subsequent in vivo investigations provided evidence that melatonin could inhibit breast tumor induction [2] [3] [4] . Since then, both laboratory and population-based studies have implicated melatonin in cancer etiology and progression through a number of mechanisms, including direct anti-proliferative effects on breast cancer cells, interaction with the estrogen pathway, stimulation of the immune system, and interactions with estrogen and insulin pathway members. The melatonin receptors 1a and 1b (MTNR1a and MTNR1b, respectively) are largely responsible for mediating the downstream effects of melatonin, while arylalkylamine Nacetyltransferase (AANAT) is the major enzyme in melatonin synthesis and controls the day/night rhythm of melatonin production in the pineal gland [5, 6] . All three have been identified as potentially important players in mediating breast cancer risk [7] [8] [9] [10] . Studies have demonstrated that polymorphisms in the melatonin receptors are associated with blood glucose levels, insulin secretion, rheumatoid arthritis, and idiopathic scoliosis, suggesting a functional role for these variants [11] [12] [13] [14] [15] , possibly due to altered protein production or function. To date, however, no studies of genetic variation in melatonin pathway genes and breast cancer risk have been conducted. Therefore, this study was undertaken to comprehensively characterize the role of common genetic variation in relation in the MTNR1a, MTNR1b and AANAT genes to breast cancer risk among participants of the Shanghai Breast Cancer Study (SBCS).
Materials and methods
Study participants were from the SBCS, a large, two-stage, population-based, case-control study of incident breast cancer among women of urban Shanghai, which has previously been described in detail [16, 17] . Cases were identified via the use of a rapid case-ascertainment system (Stage I) and the Shanghai Cancer Registry (Stages I and II). The Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix) was utilized to characterize a total of 8 SNPs in the MTNR1a gene, 9 SNPs in the MTNR1b gene, and 6
SNPs in the AANAT gene. These haplotype tagging SNPs were selected based on Han Chinese HapMap Project data using the Tagger program to capture SNPs with a minor allele frequency (MAF) of at least 5% with an r 2 C 90%. Blinded duplicated samples and quality controls were included in the genotyping. All SNPs included in this analysis had concordance rates of at least 95% among duplicates within each platform and an average call rate of 99.8%. Hardy-Weinberg equilibrium (HWE) was assessed among controls by comparing the observed-to-expected genotype frequencies using the v 2 test. Logistic regression was utilized to calculate odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for the association between genotype and breast cancer risk, while adjusting for age, education, and study stage when appropriate. Additive, dominant, recessive, and allelic models were considered. Multiplicative interactions between genetic variants and menopausal status were evaluated by comparing estimates of effect across strata for heterogeneity, as well as the statistical significance of interactions terms included in logistic regression models. The Adaptive Rank Truncated Product (ARTP) Method was utilized to produce an adjusted P value for minimum P value (MinP) to limit the effect of multiple comparisons when testing the null hypothesis that a collection of SNPs within a given gene is not associated with breast cancer risk [18] . Ten truncation points and 3,000 permuted datasets were used in the calculations. All statistical tests were 2-tailed and P B 0.05 values were considered statistically significant. Analyses were conducted using SAS v9.2 (SAS Institute, Cary, NC).
Results
This study included a total of 4,156 women, of which 2,213 were enrolled in Stage I and 1,943 were enrolled in Stage II. Women in both study stages were comparable with respect to most demographic characteristics and breast cancer risk factors ( Table 1) . As expected, cases reported a significantly earlier age at menarche and older age at menopause. Additionally, cases were more like to have breast cancer among a first-degree family member, a higher body mass index (BMI), a higher waist-to-hip ratio (WHR), and were less likely to engage in regular physical activity compared with controls.
A total of 23 haplotype-tagging SNPs were genotyped in this study. Eight were excluded from the analysis due to MAFs of less than 5% (rs16968964, rs11077821, rs9895222, rs11077823, rs4601728, rs12804291, rs12272268, and rs12275765), and one (rs1080964) was excluded due to deviation from HWE among controls. Estimates of effect derived under additive, dominant, and recessive models are presented in Table 2 for all women combined. Although a number of SNPs were significantly associated with breast cancer risk in the stage-specific analysis (data not shown), only two SNPs, rs7665392 and rs10765576, were found to have associations consistent within both study stages. However, P-values generated via the ARTP method to adjust for multiple comparisons suggest that among all women, there did not appear to be a significant association between the collection of SNPs in any single melatonin pathway gene and breast cancer risk (P value = 0.30, 0.65, and 0.35 for MTNR1a, MTNR1b, and AANAT, respectively). Given that previous studies have suggested that melatonin pathway effects may be mediated via interaction with estrogen pathway members, we conducted a stratified analysis to determine if the association between genetic variants and breast cancer risk differed by menopausal status (Table 3) . With the exception of one variant (rs7665392), we found no difference in effect by menopausal status under additive, dominant, or recessive models (data not shown).
Finally, given evidence for an interaction between menopausal status and MTNR1a rs7665392, we examined the association between this SNP and breast cancer risk among other measures of estrogen exposure (Table 4) . Although there were no significant interactions between age at menarche, years of menstruation, and total months of breast feeding and the rs7665392 SNP in relation to breast cancer risk, the direction of the associations were consistent with those found for menopausal status.
Discussion
We systematically evaluated common genetic variation among melatonin pathway genes in relation to breast cancer risk in a large, two-stage, population-based study of Chinese women. A total of 23 SNPs were genotyped in the MTNR1a, MTNR1b, and AANAT genes. We found that MTNR1a polymorphism rs10765576 was significantly associated with altered breast cancer risk under a recessive model. While there was no evidence for an overall effect of MTNR1a rs7665392 with breast cancer risk, we found evidence of a significant interaction (P = 0.001) between menopausal status and the rs7665392 polymorphism. No association with breast cancer risk was found for SNPs in the AANAT gene.
To our knowledge, this investigation is the first to evaluate the association between common genetic variants in the aforementioned genes and cancer risk. Previous studies of genetic variation in the MTNR1a, MTNR1b, and AANAT genes have assessed their association with outcomes such as scoliosis, major depression, diabetes, blood glucose levels, polycystic ovary syndrome (PCOS), and schizophrenia. There is a single published investigation of AANAT polymorphisms in which Wang et al. [19] found no association with idiopathic scoliosis in Han Chinese.
Similarly, epidemiologic evidence is limited for the role of genetic variants in the MTNR1a gene and disease outcomes. Haplotypes in the MTNR1a gene were found to be associated with non-tardive dyskinesia among schizophrenic inpatients receiving long-term antipsychotic treatment [20] . Another research group found no evidence for an association between MTNR1a polymorphisms and adolescent idiopathic scoliosis [21] . Our findings of a significant interaction between MTNR1a and menopausal status are consistent with in vitro data. Girgert et al. [22] reported that membrane-bound melatonin receptor MT1 (MTNR1a) down-regulates estrogen responsive genes in breast cancer cells and that the more melatonin receptors the cell line expressed, the stronger the reduction in estradiol-induced genes, including p53, p21 WAF , and c-myc. We might hypothesize that the rs7665392 variant, or a yet unidentified functional variant in high linkage disequilibrium with this polymorphism, leads to decreased expression or function of the MTNR1a receptor and subsequently increased levels of estradiolinduced genes among pre-menopausal women with higher levels of estrogen. This interaction with the estrogen pathway and mechanism for increase in estradiol-induced genes is a plausible explanation for how the rs7665392 variant might alter breast cancer risk. Furthermore, there have been six non-synonymous low frequency (\5% MAF) [23] . Further investigation to elucidate the function of the rs7665392 or its linkage to other potentially function variants is warranted. In contrast to the AANAT and MTNR1a genes, there is more extensive characterization of MTNR1b variants. The majority of reports have focused on the relationship with insulin-related outcomes, sleep disturbances, and scoliosis, with no reports of cancer risk as an outcome. An investigation among Han Chinese women found an association between both the rs10830963 minor allele genotypes and minor alleles and increased predisposition for PCOS, and was also associated with higher fasting plasma glucose concentrations [24] . The rs10830963 polymorphism, as well as the rs10830962 polymorphism that is frequently reported in high linkage with it in other studies, has also been found to be significantly associated with impaired fasting plasma glucose, reduced b-cell function, and increased diabetes risk [25] [26] [27] [28] [29] [30] [31] [32] . However, neither rs10830963 nor rs10830962 appeared to play a role in breast cancer risk in our population. A number of additional SNPs in the MTNR1b gene that have also been identified as playing a role in pre-diabetes. Although there is no functional information in the literature regarding the SNP we found to be associated in this study (rs10765576), this variant is in high linkage (r 2 = 0.97) with the rs4753426 variant, which was significantly associated with impaired fasting glucose and b-cell function in another study [25] .
Given that a number of polymorphisms in the MTNR1b gene have been associated with altered function of insulin pathway members, it is not necessarily a concern that we did not observe associations with breast cancer risk across all the variants we evaluated in this study. It is possible that some polymorphisms have a greater effect on function than others. Additionally, the SNPs that have been found to be associated with altered function of insulin pathway members are generally only in moderate linkage disequilibrium, and thus do not reflect the same underlying association signal [33] . Given more recent evidence of the role of insulin and related pathway members in breast cancer etiology, it is a plausible mechanism by which variants in the MTNR1b pathway may alter breast cancer risk.
Study strengths included a large, two-stage, populationbased study design. The large sample size also allowed for subgroup analysis by menopausal status. In terms of limitations, infrequent variation (\5% MAF) among our study population with respect to the SNPs included in the Affy Chip 6.0 for the AANAT gene precluded full characterization of its disease associations. Fine mapping to further assess low frequency SNPs in relationship to breast cancer risk in this gene is warranted, as we cannot rule out that one of these low frequency variants may be associated with breast cancer risk. Furthermore, given evidence of significant differences in circadian and melatonin genetic variations among worldwide populations [34] , these results should be confirmed in other ethnic groups.
In summary, results from these analyses suggest that common genetic variation in the MTNR1a and 1b genes may contribute to breast cancer susceptibility, and that the effect associated with the rs7665392 polymorphism may vary by menopausal status. Given that previous studies have demonstrated that a number of variants in the MTNR1b genes are associated with altered function or expression of insulin and glucose family members, and this pathway has been implicated in breast cancer risk, further research may focus on clarifying the potential relationship between melatonin pathway genes, the insulin pathway, and breast cancer risk.
